Views & Analysis | Perspectives on pharma industry issues

R&D

Why every healthcare breakthrough creates a new education ch...

Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.

Sales & Marketing

Female HCP in her office on phone holding clipboard of patient information

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Articles

Is it time for pharma to build a dialogue with patients? (pa...

With pharma facing increasing challenges, Mat Phillips questions whether it’s time for them to start reaching out to patients in order to regain some trust. The pharmaceutical industry, perhaps for the first time, is facing an almost ‘perfect storm’ of challenges, and having to…

Articles

Maintaining momentum through mergers and acquisitions

Shareholders like the prospect of a big merger or acquisition, but pharmaphorum hears how keeping employees and customers on board are the real keys to success. As pharma looks for further innovation and diversification to maintain growth, the appetite for acquisitions and mergers seems to continue unabated…

Articles

How to get more value out of the products you already have

Despite many new products coming to market to replace patent expired products the lost revenue isn't necessarily being replaced. Andree Bates questions how we can get more value out of our existing products. Many large brands have already undergone patent expiry or are about to undergo such a change. This includes: Lipitor, Plavix, Seretide, Seroquel...

Sales & Marketing

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology